Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

That’s where injectables like Ozempic come in. GLP-1 supplement makers claim that their products work similarly to weight loss injections, but without the poke, using natural plant compounds ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...